Neonatal hypoglycemia and its management. (5 Marks)(KMCRI)** *Neonatal Hypoglycemia. (5 Marks) (GMC)

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I have enough content from the textbooks. Let me now compile a comprehensive, exam-ready answer.

Neonatal Hypoglycemia

Definition

Neonatal hypoglycemia is defined as a serum glucose level insufficient to meet metabolic requirements. For practical clinical purposes:

Point-of-care glucose (POCG) < 45-50 mg/dL within the first 48 hours of life
< 70 mg/dL beyond 48 hours of life
A common threshold used in term and late preterm infants: serum glucose < 40 mg/dL

Note: Bedside glucometers can be inaccurate by 10-15 mg/dL in the hypoglycemic range. A STAT plasma glucose must always be sent to confirm the diagnosis.

Incidence

Affects approximately 15-25% of neonates born to women with diabetes
Less common when tight maternal glycemic control is maintained during pregnancy and labor

Pathophysiology

After birth, the continuous transplacental glucose supply is abruptly cut. The neonate depends on:

Glycogenolysis (breakdown of liver glycogen stores)
Gluconeogenesis (from amino acids, lactate, glycerol)
Lipolysis (free fatty acids as alternative fuel)

Failure of any of these mechanisms - or excessive glucose utilization (e.g., hyperinsulinemia) - leads to hypoglycemia.

Risk Factors / Causes

Classified into three broad categories:

1. Decreased Glucose Production / Substrate Deficiency

Cause	Mechanism
Prematurity / SGA (IUGR)	Reduced hepatic glycogen stores, impaired gluconeogenesis
Perinatal asphyxia	Increased glucose consumption during anaerobic metabolism
Hypothermia	Depletes glycogen stores through thermogenesis
Polycythemia	Increased glucose utilization by excess RBCs
Sepsis / shock	Impaired gluconeogenesis, increased utilization

2. Hyperinsulinemia (Excess Glucose Utilization)

Cause	Notes
Infant of Diabetic Mother (IDM)	Most common cause in first 48 hours; transient due to chronic fetal hyperglycemia stimulating fetal beta cells
Beckwith-Wiedemann syndrome	Macroglossia, omphalocele, macrosomia + hypoglycemia
Congenital Hyperinsulinism	Dominant or recessive mutations in genes regulating beta-cell insulin secretion (most common cause beyond day 7)
Perinatal asphyxia / IUGR	Transient hyperinsulinemia
Maternal drug use	Terbutaline, beta-blockers, oral hypoglycemics

3. Endocrine / Metabolic Disorders

Hypopituitarism - Low GH and cortisol (look for midline defects, micropenis)
Congenital adrenal hyperplasia
Inborn errors of metabolism - fatty acid oxidation defects (e.g., MCAD deficiency), glycogen storage diseases

Clinical Features

Asymptomatic Hypoglycemia

May be detected only on routine screening in at-risk neonates

Symptomatic Hypoglycemia

Neurogenic (adrenergic) symptoms:

Jitteriness / tremors
Tachycardia, diaphoresis, pallor

Neuroglycopenic symptoms:

Hypotonia, lethargy
Poor feeding, weak cry
Apnea, cyanosis
Seizures (may be subtle - eye deviation, lip smacking, tonic posturing)
Coma (severe cases)

Untreated or undertreated neonatal hypoglycemia may lead to seizures, coma, and permanent brain damage, particularly when hypoglycemia persists beyond 2-24 hours (Creasy & Resnik's Maternal-Fetal Medicine).

Investigations / Workup

Bedside glucometer - Screening tool only (may be inaccurate by 10-15 mg/dL)
STAT plasma/serum glucose - Required for confirmed diagnosis

Additional workup if serum glucose consistently < 70 mg/dL after 48 hours:

Serum insulin, C-peptide
Growth hormone, cortisol
Free fatty acids, beta-hydroxybutyrate
Complete blood count with differential
Blood, urine, CSF cultures (if sepsis suspected)
Urinalysis

Glucagon stimulation test (interpret results):

Rise in glucose ≥ 30 mg/dL + plasma insulin > 2 µU/mL + low free fatty acids (< 1.5 mmol/L) + low beta-hydroxybutyrate (< 2 mmol/L) + glucose requirement > 8 mg/kg/min → Hyperinsulinemia
Low GH + low cortisol at time of hypoglycemia + midline defects + micropenis → Hypopituitarism

Management

Treatment Goals

Population	Target glucose
High-risk neonates (no congenital disorder) < 48 hrs	Plasma glucose > 45-50 mg/dL
High-risk neonates (no congenital disorder) > 48 hrs	Plasma glucose > 60 mg/dL
Confirmed congenital hypoglycemia disorder	Plasma glucose > 70 mg/dL

Step-by-Step Management

Step 1: Asymptomatic hypoglycemia in a stable neonate

Encourage early and frequent breastfeeding (every 1-2 hours)
Monitor glucose every 30-60 minutes until stable
Dextrose gel (40% buccal dextrose, 0.5 mL/kg) can be used as an adjunct

Step 2: Symptomatic hypoglycemia OR glucose < 40 mg/dL

IV Dextrose bolus: D10W at 2 mL/kg (= 200 mg/kg glucose) administered over 2-5 minutes
Followed immediately by a continuous IV dextrose infusion

Step 3: IV Glucose Infusion Rate (GIR)

Starting GIR: 6-8 mg/kg/min (using D10W at 80-100 mL/kg/day)
Formula: GIR (mg/kg/min) = % Dextrose × rate (mL/hr) / (weight in kg × 6)
Adjust GIR by no more than 2 mg/kg/min every 2 hours
Monitor glucose every 30-60 minutes until stable, then 1-2 hourly

Step 4: Persistent / Refractory Hypoglycemia

Drug	Dose	Mechanism
Glucagon	0.02-0.03 mg/kg IV/IM/SC (max 1 mg)	Promotes glycogenolysis and gluconeogenesis
Diazoxide	5-15 mg/kg/day PO in 3 divided doses	Keeps beta-cell K-ATP channels open → inhibits insulin secretion (1st-line for congenital hyperinsulinism)
Hydrocortisone	5-10 mg/kg/day	For adrenal insufficiency / persistent hypoglycemia unresponsive to glucose
Octreotide	2-10 mcg/kg/day SC	Somatostatin analog; inhibits insulin secretion (2nd-line for hyperinsulinism)

Diazoxide carries a black box warning for pulmonary hypertension (rare but serious).

Step 5: Surgical management

Near-total pancreatectomy for diffuse congenital hyperinsulinism refractory to medical therapy

Weaning IV Glucose

Once glucose is stable for > 12-24 hours and oral feeds are established, wean GIR gradually (by 2 mg/kg/min every 2 hours)
Never abrupt discontinuation - can cause rebound hypoglycemia

Prognosis / Complications

Infants hypoglycemic for 2-24 hours or > 24 hours have significantly lower neurodevelopmental (adaptability) scores at age 2 years compared to controls
Prolonged neonatal hypoglycemia increases risk of: cerebral palsy, epilepsy, learning difficulties, visual impairment
IDM mothers who gained excess weight had infants with longer duration of hypoglycemia

Prevention

Tight maternal glycemic control during pregnancy and labor (reduces incidence significantly)
Early skin-to-skin contact and breastfeeding within first hour
Glucose screening protocol for all at-risk neonates (IDM, prematurity, SGA, LGA, perinatal asphyxia)

Key Sources:

The Harriet Lane Handbook, 23rd Edition (Johns Hopkins) - Ch. 10 & 18
Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice
Pediatric Endocrine Society Guidelines (J Pediatr. 2015;167(2):238-245)

This is a shared conversation. Sign in to Orris to start your own chat.